Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $97.6, a high estimate of $103.00, and a low estimate of $93.00. This upward trend ...
Truist analyst Richard Newitter lowered the firm’s price target on Globus Medical (GMED) to $82 from $90 and keeps a Hold rating on the shares.
In a report released today, Richard Newitter from Truist Financial maintained a Hold rating on Globus Medical (GMED – Research Report). The ...
MedPage Today celebrated its 20th anniversary on March 15. To get a sense of its early days -- and the new ground it was ...
Globus Medical, Inc. reported $657,293 million in sales and $60,275 million in operating profit for the quarter ending December 31, 2024, which was above both Wall Street’s expectations and management ...